In Vitro Study of Interleukin-6 when Used at Low Dose and Ultra-Low Dose in Micro-Immunotherapy

Overview

Journal Life (Basel)

Specialty Biology

Date 2024 Mar 28

PMID 38541700

Authors

Camille Jacques

Flora Marchand

Mathias Chatelais

Adrien Brulefert

Mathieu Riffault

Ilaria Floris

Affiliations

Soon will be listed here.

Abstract

As one of the major cytokines implicated in the orchestration of immune responses, interleukin 6 (IL-6) can either act as a pro- or an anti-inflammatory factor, depending on the micro-environment. In micro-immunotherapy (MI) medicines, IL-6 is employed at low doses (LD) and ultra-low doses (ULD), expressed in centesimal Hahnemannian (CH), and used alone or in combination with other immune regulators to modulate patients' immune responses. The present study focused on assessing the in vitro immune-modulatory effects of two IL-6-containing MI products: (i) the unitary IL-6 (4 CH) and (ii) the complex MI-medicine (MIM) 2LALERG, which includes IL-6 (17 CH) in association with other actives in its formulation. Our results showed that IL-6 (4 CH) activated granulocytes under basal conditions, and natural killer cells in the presence of an anti-CD3 signal, as assessed by their CD69 expression. In addition, IL-6 (4 CH) balanced the macrophages' differentiation toward a M2a profile. On the other hand, the tested 2LALERG capsule inhibited the histamine degranulation of rats' peritoneal mast cells and reduced the release of IL-6 itself in inflamed human macrophages. Altogether, these data provide novel pieces of evidence on the double-edged potential of the LD and ULD of IL-6 in immune responses modulation, when employed in MI.

References

Jacques C, Floris I, Lejeune B . Ultra-Low Dose Cytokines in Rheumatoid Arthritis, Three Birds with One Stone as the Rationale of the 2LARTH Micro-Immunotherapy Treatment. Int J Mol Sci. 2021; 22(13). PMC: 8268272. DOI: 10.3390/ijms22136717. View

Hirano T, Ishihara K, Hibi M . Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 2000; 19(21):2548-56. DOI: 10.1038/sj.onc.1203551. View

Kang Y, Jeung I, Park A, Park Y, Jung H, Kim T . An increased level of IL-6 suppresses NK cell activity in peritoneal fluid of patients with endometriosis via regulation of SHP-2 expression. Hum Reprod. 2014; 29(10):2176-89. DOI: 10.1093/humrep/deu172. View

Mestas J, Hughes C . Of mice and not men: differences between mouse and human immunology. J Immunol. 2004; 172(5):2731-8. DOI: 10.4049/jimmunol.172.5.2731. View

Agorastos A, Hauger R, Barkauskas D, Moeller-Bertram T, Clopton P, Haji U . Circadian rhythmicity, variability and correlation of interleukin-6 levels in plasma and cerebrospinal fluid of healthy men. Psychoneuroendocrinology. 2014; 44:71-82. DOI: 10.1016/j.psyneuen.2014.02.020. View

Ferra-Canellas M, Munar-Bestard M, Floris I, Ramis J, Monjo M, Garcia-Sureda L . A Sequential Micro-Immunotherapy Medicine Increases Collagen Deposition in Human Gingival Fibroblasts and in an Engineered 3D Gingival Model under Inflammatory Conditions. Int J Mol Sci. 2023; 24(13). PMC: 10341409. DOI: 10.3390/ijms241310484. View

Hirano T . IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2020; 33(3):127-148. PMC: 7799025. DOI: 10.1093/intimm/dxaa078. View

Jin J, Han X, Yu Q . Interleukin-6 induces the generation of IL-10-producing Tr1 cells and suppresses autoimmune tissue inflammation. J Autoimmun. 2012; 40:28-44. PMC: 3524403. DOI: 10.1016/j.jaut.2012.07.009. View

Fischer M, Goldschmitt J, Peschel C, Brakenhoff J, Kallen K, Wollmer A . I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol. 1997; 15(2):142-5. DOI: 10.1038/nbt0297-142. View

10.

Yoshimura A, Naka T, Kubo M . SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol. 2007; 7(6):454-65. DOI: 10.1038/nri2093. View

11.

Schwab G, Siegall C, Aarden L, Neckers L, Nordan R . Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood. 1991; 77(3):587-93. View

12.

Hurst S, Wilkinson T, McLoughlin R, Jones S, Horiuchi S, Yamamoto N . Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 2001; 14(6):705-14. DOI: 10.1016/s1074-7613(01)00151-0. View

13.

Lacroix S, Chang L, Rose-John S, Tuszynski M . Delivery of hyper-interleukin-6 to the injured spinal cord increases neutrophil and macrophage infiltration and inhibits axonal growth. J Comp Neurol. 2002; 454(3):213-28. DOI: 10.1002/cne.10407. View

14.

Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M . Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005; 5(12):1731-40. DOI: 10.1016/j.intimp.2005.05.010. View

15.

Mullberg J, Schooltink H, Stoyan T, Gunther M, Graeve L, Buse G . The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol. 1993; 23(2):473-80. DOI: 10.1002/eji.1830230226. View

16.

Mould K, Moore C, McManus S, McCubbrey A, McClendon J, Griesmer C . Airspace Macrophages and Monocytes Exist in Transcriptionally Distinct Subsets in Healthy Adults. Am J Respir Crit Care Med. 2020; 203(8):946-956. PMC: 8048748. DOI: 10.1164/rccm.202005-1989OC. View

17.

Vivier E, Raulet D, Moretta A, Caligiuri M, Zitvogel L, Lanier L . Innate or adaptive immunity? The example of natural killer cells. Science. 2011; 331(6013):44-9. PMC: 3089969. DOI: 10.1126/science.1198687. View

18.

Floris I, Rose T, Rojas J, Appel K, Roesch C, Lejeune B . Pro-Inflammatory Cytokines at Ultra-Low Dose Exert Anti-Inflammatory Effect In Vitro: A Possible Mode of Action Involving Sub-Micron Particles?. Dose Response. 2021; 18(4):1559325820961723. PMC: 7829609. DOI: 10.1177/1559325820961723. View

19.

Desai A, Jung M, Olivera A, Gilfillan A, Prussin C, Kirshenbaum A . IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3. J Allergy Clin Immunol. 2016; 137(6):1863-1871.e6. PMC: 4899186. DOI: 10.1016/j.jaci.2015.09.059. View

20.

Atri C, Guerfali F, Laouini D . Role of Human Macrophage Polarization in Inflammation during Infectious Diseases. Int J Mol Sci. 2018; 19(6). PMC: 6032107. DOI: 10.3390/ijms19061801. View